SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
M Lipsitch, F Krammer, G Regev-Yochay… - Nature Reviews …, 2022 - nature.com
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
2) in fully vaccinated individuals are receiving intense scrutiny because of their importance …
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …
associated mortality than the general population. Owing to this increased risk, patients with …
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
N Raje, K Anderson, H Einsele, Y Efebera, F Gay… - Blood cancer …, 2023 - nature.com
Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …
Adaptive immune responses and immunity to SARS-CoV-2
Since the onset of the COVID-19 pandemic, the medical field has been forced to apply the
basic knowledge of immunology with the most up-to-date SARS-CoV-2 findings and …
basic knowledge of immunology with the most up-to-date SARS-CoV-2 findings and …
The role of vaccines in the COVID-19 pandemic: what have we learned?
F Krammer - Seminars in Immunopathology, 2024 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple
myeloma; however, serious infections have emerged as important toxicities. In this …
myeloma; however, serious infections have emerged as important toxicities. In this …
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR
Fast, high-throughput methods for measuring the level and duration of protective immune
responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here …
responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here …
Learning through a pandemic: the current state of knowledge on COVID-19 and cancer
The ongoing coronavirus disease 2019 (COVID-19) pandemic has left patients with current
or past history of cancer facing disparate consequences at every stage of the cancer …
or past history of cancer facing disparate consequences at every stage of the cancer …
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
Despite the efficacy of COVID-19 vaccines in healthy individuals, multiple myeloma (MM)
patients are immunocompromised and mount suboptimal humoral and cellular responses …
patients are immunocompromised and mount suboptimal humoral and cellular responses …